



5.21.176

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2024
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	June 11, 2021
<b>Subject:</b>	Rybrevent	<b>Page:</b>	1 of 5

---

**Last Review Date:** June 13, 2024

---

## Rybrevent

### Description

#### Rybrevent (amivantamab-vmjw)

---

#### Background

Rybrevent (amivantamab-vmjw) is a bispecific antibody that binds to the extracellular domains of epidermal growth factor receptor (EGFR) and MET. In studies, Rybrevent was able to disrupt EGFR and MET signaling functions through blocking ligand binding and, in exon 20 insertion mutation models, degradation of EGFR and MET. The presence of EGFR and MET on the surface of tumor cells also allows for targeting of these cells for destruction by immune effector cells, such as natural killer cells and macrophages, through antibody-dependent cellular cytotoxicity and trogocytosis mechanisms, respectively (1).

#### Regulatory Status

FDA-approved indication: Rybrevent is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: (1)

- In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test.
- As a single agent for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2024
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	June 11, 2021
<b>Subject:</b>	Rybrevant	<b>Page:</b>	2 of 5

---

Rybrevant has warnings regarding the following: infusion-related reactions, interstitial lung disease/pneumonitis, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity (1).

Rybrevant can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised to use effective contraception during treatment and for 3 months after the final dose of Rybrevant (1).

Patients should be premedicated with antihistamines, antipyretics, and glucocorticoids as appropriate to reduce the risk of infusion-related reactions (1).

The safety and effectiveness of Rybrevant in pediatric patients less than 18 years of age have not been established (1).

---

## Related policies

### Policy

*This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.*

Rybrevant may be considered **medically necessary** if the conditions indicated below are met.

Rybrevant may be considered **investigational** for all other indications.

## Prior-Approval Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)
  - a. EGFR exon 20 insertion mutation as detected by an FDA-approved test
  - b. Patient has **ONE** of the following:

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2024
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	June 11, 2021
<b>Subject:</b>	Rybrevant	<b>Page:</b>	3 of 5

---

- i. Used in combination with carboplatin and pemetrexed for first-line treatment
- ii. Used as a single agent **AND** disease has progressed on or after platinum-based chemotherapy

**AND ALL** of the following:

1. Patient will be premedicated with antihistamines, antipyretics, and glucocorticoids as appropriate
2. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Rybrevant and for 3 months after the final dose

---

## Prior – Approval *Renewal* Requirements

**Age** 18 years of age or older

### Diagnosis

Patient must have the following:

1. Locally advanced or metastatic non-small cell lung cancer (NSCLC)

**AND ALL** of the following:

1. **NO** disease progression or unacceptable toxicity
2. Patient will be premedicated with antihistamines, antipyretics, and glucocorticoids as appropriate
3. Female patients of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Rybrevant and for 3 months after the final dose

## Policy Guidelines

### Pre - PA Allowance

None

### Prior - Approval Limits

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2024
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	June 11, 2021
<b>Subject:</b>	Rybrevant	<b>Page:</b>	4 of 5

---

**Duration** 12 months

---

## Prior – Approval *Renewal* Limits

Same as above

### Rationale

#### Summary

Rybrevant (amivantamab-vmjw) is a bispecific antibody that binds to the extracellular domains of epidermal growth factor receptor (EGFR) and MET. It is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations. Rybrevant has warnings regarding the following: infusion-related reactions, interstitial lung disease/pneumonitis, dermatologic adverse reactions, ocular toxicity, and embryo-fetal toxicity. The safety and effectiveness of Rybrevant in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Rybrevant while maintaining optimal therapeutic outcomes.

#### References

1. Rybrevant [package insert]. Horsham, PA: Janssen Biotech, Inc.; March 2024.
2. NCCN Drugs & Biologics Compendium<sup>®</sup> Amivantamab-vmjw 2024. National Comprehensive Cancer Network, Inc. Accessed on May 15, 2024.

### Policy History

Date	Action
June 2021	Addition to PA
September 2021	Annual review and reference update
March 2022	Annual review and reference update
September 2023	Annual review and reference update
March 2024	Annual review and reference update
April 2024	Per PI update, added indication of NSCLC in combination with carboplatin and pemetrexed for first-line treatment. Also removed quantity limits
June 2024	Annual review and reference update

### Keywords

---

# 5.21.176

---

<b>Section:</b>	Prescription Drugs	<b>Effective Date:</b>	July 1, 2024
<b>Subsection:</b>	Antineoplastic Agents	<b>Original Policy Date:</b>	June 11, 2021
<b>Subject:</b>	Rybrevant	<b>Page:</b>	5 of 5

---

**This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 13, 2024 and is effective on July 1, 2024.**